Ban Poisonous Additives Act of 2011

Ban Poisonous Additives Act of 2011; Preservation of Antibiotics for Medical Treatment Act of 2011; White House Conference on Food and Nutrition Act; Trans Fat Truth in Labeling Act of 2011; Poison-Free Poultry Act of 2011; Downed Animal and Food Safety Protection Act; REAL Beef Act; [H.R.432][H.R.965][H.R.1382][H.R.1486][H.R.1487][H.R.3704][H.R.4346] Food Safety Accountability Act of 2011; Foodborne Illness Reduction Act of 2011; Farm Bill [S.136][S.216][S.1157][S.1211][S.1529][S.3240]

Client expense: $47,484 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, White House Office

HR 432 Ban Poisonous Additives Act of 2011 S 136 Ban Poisonous Additives Act of 2011 Senate Agriculture Appropriations Bill Senate Labor Health & Human Services Appropriations Bill

Client expense: Not reported · Firm income: $40,000

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R.4395, the Cosmetic Safety Amendments Act of 2012 The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics. H.R. 4262, the Cosmetics Safety Enhancement Act of 2012 The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. S. 3237, the Accelerating the End of Breast Cancer Act of 2012. The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, opposing appropriations riders limiting the work of the National Toxicology Program's Report on Carcinogens, and increasing support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $30,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE

S 136 Ban Poisonous Additives Act of 2011- A bill to ban the use of bisphenol A in food containers, and for other purposes. All Provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products. HR 432-Ban Poisons Additives Act of 2011-A bill to ban Bis- phenol-A from all Food contact uses. All provisions related to banning Bisphenol-A.

Client expense: $1,290,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 432-Poisonous Additives Act of 2011 Front of Pack Labeling School Nutrition Standards

Client expense: $90,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

S 136 "Ban Poisonous Additives Act of 2011" to establish requirements with respect to Bisphenol A HR 432 "Ban Poisonous Additives Act of 2011" to ban the use of Bisphenol A in food containers and for other purposes FDA funding S 3187 the Food and Drug Administration and Innovation Act

Client expense: $250,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Ban Poisonous Additives Act of 2011; Preservation of Antibiotics for Medical Treatment Act of 2011; White House Conference on Food and Nutrition Act; Trans Fat Truth in Labeling Act of 2011; Poison-Free Poultry Act of 2011; Downed Animal and Food Safety Protection Act; REAL Beef Act; [H.R.432][H.R.965][H.R.1382][H.R.1486][H.R.1487][H.R.3704][H.R.4346] Food Safety Accountability Act of 2011; Foodborne Illness Reduction Act of 2011; Farm Bill [S.136][S.216][S.1157][S.1211][S.1529][S.3240]

Client expense: $95,408 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, White House Office

Ban Poisonous Additives Act of 2011; Preservation of Antibiotics for Medical Treatment Act of 2011; White House Conference on Food and Nutrition Act; Trans Fat Truth in Labeling Act of 2011; Poison-Free Poultry Act of 2011; Downed Animal and Food Safety Protection Act; REAL Beef Act; [H.R.432][H.R.965][H.R.1382][H.R.1486][H.R.1487][H.R.3704][H.R.4346] Food Safety Accountability Act of 2011; Foodborne Illness Reduction Act of 2011; Farm Bill [S.136][S.216][S.1157][S.1211][S.1529][S.3240]

Client expense: $50,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, White House Office

HR 432 Ban Poisonous Additives Act of 2011 S 136 Ban Poisonous Additives Act of 2011 Senate Agriculture Appropriations Bill Senate Labor Health & Human Services Appropriations Bill

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

HR 432/ S136 Ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) HR 4223 The "Safe Doses Act"; (All provisions of the bill.) HR 3668 The "Counterfeit Drug Penalty Enhancement Act of 2011"; (All parts.) HR 4216 The "Foreign Counterfeit Prevention Act"; (All parts.) Draft Discussion of FDA User Fees; (All parts) S 365 Balanced Budget Control Act of 2011; (Sections pertaining to healthcare expenditures, Medicare Part D drug benefits.) Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic reporting and stop sale.) HR 2245 the Preserving Access to Life Saving Medications Act; (Provisions relating drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11.) HR 965/S 1211 The Federal Food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases; (Title II. General provisions of the bill.) HR 436 Health Care Cost Reduction Act of 2012; (Provisions related to medical device taxes.) Safe Injection Practices (no bill number); (Provisions related to safer injection practices.)

Client expense: $1,450,321 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 432/S 136 Ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.)

Client expense: $1,450,321 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 136 "Ban Poisonous Additives Act of 2011" to establish requirements with respect to Bisphenol A HR 432 "Ban Poisonous Additives Act of 2011" to ban the use of bisphenol A in food containers and for other purposes S 3187 the Food and Drug Administration Safety and Innovation Act

Client expense: $290,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES

H.R. 432-Poisonous Additives Act of 2011 Front of Pack Labeling School Nutrition Standards

Client expense: $90,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R.4395, the Cosmetic Safety Amendments Act of 2012 The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics. H.R. 4262, the Cosmetics Safety Enhancement Act of 2012 The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. S. 3237, the Accelerating the End of Breast Cancer Act of 2012. The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $30,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

Develop a strategy with respect to legislation aimed at banning or limiting the use of Bisphenol A. H.R. 432/S. 136. Ban Poisonous Additives Act of 2011.

Client expense: Not reported · Firm income: $10,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Develop a strategy with respect to legislation aimed at banning or limiting the use of Bisphenol A to ban the use of bisphenol A in food containers, and for other purposes: H.R. 432/S. 136. Ban Poisonous Additives Act of 2011.

Client expense: Not reported · Firm income: $10,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 432 Ban Poisonous Additives Act of 2011 S 136 Ban Poisonous Additives Act of 2011

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

Ban Poisonous Additives Act of 2011; Preservation of Antibiotics for Medical Treatment Act of 2011; White House Conference on Food and Nutrition Act; Trans Fat Truth in Labeling Act of 2011; Poison-Free Poultry Act of 2011; Downed Animal and Food Safety Protection Act; REAL Beef Act; [H.R.432] [H.R.965] [H.R.1382] [H.R.1486] [H.R.1487] [H.R.3704] [H.R.4346] Food Safety Accountability Act of 2011; Foodborne Illness Reduction Act of 2011; Farm Bill [S.136] [S.216] [S.1157] [S.1211] [S.1529] [S.3240]

Client expense: $50,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, White House Office

Ban Poisonous Additives Act of 2011; Preservation of Antibiotics for Medical Treatment Act of 2011; White House Conference on Food and Nutrition Act; Trans Fat Truth in Labeling Act of 2011; Poison-Free Poultry Act of 2011; Downed Animal and Food Safety Protection Act; REAL Beef Act [H.R.432] [H.R.965] [H.R.1382] [H.R.1486] [H.R.1487] [H.R.3704] [H.R.4346] Food Safety Accountability Act of 2011; Foodborne Illness Reduction Act of 2011 [S.136] [S.216] [S.1157] [S.1211] [S.1529]

Client expense: $63,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, White House Office

HR 432 Ban Poisonous Additives Act of 2011 S 136 Poisonous Additives Act of 2011

Client expense: Not reported · Firm income: Not reported

HR 432 Ban Poisonous Additives Act of 2011 S 136 Poisonous Additives Act of 2011

Client expense: Not reported · Firm income: Not reported

HR 965/S 1211 The Federal Food, Drug and Cosmetic Act to preserve the effectiveness of medially important antibiotics used in the treatment of human and animal diseases; (Title II. General provisions of the bill.) HR 432/S 136 Ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.) HR 436/HR 488/HR 734/S 17/S 262 Medical Device Tax Repeal; (Provisions related to entire bill.) HR 4/HR 60/HR 144/HR 584/HR 705/S 18/S 72 The Small Business Paperwork Mandate Elimination Act of 2011; (Provisions related to the 1099 repeal.) HR 141/HR 145/HR 215/HR 429/HR 636/S 16/S 193 To repeal the Patient Protection and Affordable Care Act and the health Care and Education Reconciliation Act of 2010; (Provisions related to Health Care Reform repeal.) HR 3209 HR 3204/S 1700/PL 107-250 Medical Device User Fee and Modernization Act (MDUFMA); (Provisions related to MDUFMA.) HR 4223 The Safe Doses Act; (All provisions of the bill.) HR 3668 The Counterfeit Drug Penalty Enhancement Act of 2011; (All provisions of the bill.) HR 4216 The Foreign Counterfeit Prevention Act; (All provisions of the bill.) Draft Discussion on FDA User Fees; (All parts.) S 365 Balanced Budget Control Act of 2011; (Sections pertaining to healthcare expenditures, Medicare Part D drug benefits.) Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic reporting and stop sale.) HR 2245 The Preserving Access to Life Saving Medications Act; (Drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11.)

Client expense: $1,480,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 432/S 136 Ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.)

Client expense: $1,480,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S 136 "Ban Poisonous Additives Act of 2011" to establish requirements with respect to bisphenol A HR 432 "Ban Poisonous Additives Act of 2011" to ban the use of bisphenol A in food containers and for other purposes

Client expense: $220,000 · Firm income: Not reported

Ban Poisonous Additives Act of 2011; Preservation of Antibiotics for Medical Treatment Act of 2011; White House Conference on Food and Nutrition Act; Trans Fat Truth in Labeling Act of 2011; Poison-Free Poultry Act of 2011; Downed Animal and Food Safety Protection Act; REAL Beef Act [H.R.432] [H.R.965] [H.R.1382] [H.R.1486] [H.R.1487] [H.R.3704] [H.R.4346] Food Safety Accountability Act of 2011; Foodborne Illness Reduction Act of 2011 [S.136] [S.216] [S.1157] [S.1211] [S.1529]

Client expense: $40,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, White House Office

H.R. 432-Poisonous Additives Act of 2011 Front of Pack Labeling School Nutrition Standards

Client expense: $90,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $30,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

Develop a strategy with respect to legislation aimed at banning or limiting the use of Bisphenol A to ban the use of bisphenol A in food containers, and for other purposes: H.R. 432/S. 136. Ban Poisonous Additives Act of 2011.

Client expense: Not reported · Firm income: $40,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Develop a strategy with respect to legislation aimed at banning or limiting the use of Bisphenol A. H.R. 432/S. 136. Ban Poisonous Additives Act of 2011.

Client expense: Not reported · Firm income: $40,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Preservation of Antibiotics for Medical Treatment Act of 2011; Trans Fat Truth in Labeling Act of 2011; Poison-Free Poultry Act of 2011; Downed Animal and Food Safety Protection Act; White House Conference on Food and Nutrition Act; Food Safety Accountability Act of 2011; Foodborne Illness Reduction Act of 2011 [H.R.432] [H.R.965] [H.R.1486] [H.R.1382] [H.R.1487] [H.R.3704] [S.136] [S.216] [S.1157] [S.1211] [S.1529]

Client expense: $53,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, White House Office

HR 965/S 1211 The Federal Food, Drug and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases; (Title II. General provisions in the bill.) S 365 Balanced Budget Control Act of 2011; (Sections pertaining to healthcare expenditures, Medicare Part D drug benefits.) Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic reporting and stop sale.) HR 2245 The Preserving Access to Life Saving Medications Act; (Drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11) HR 436/HR 488/HR 734/S 17/S 262 Medical Device Tax Repeal; (Provisions related to entire bill.) HR 4/HR 60/HR 144/HR 584/HR 705/S 18/S 72 The Small Business Paperwork Mandate Elimination Act of 2011; (Provisions related to the 1099 repeal.) HR 141/HR 145/HR 215/HR 429/HR 636/S 16/S 193 To repeal the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010; (Provisions related to Health Care Reform repeal.) PL 107-250 The Medical Device User Fee and Modernization Act; (Provisions related to MDUFMA.) HR 432/S 136 Ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.)

Client expense: $1,320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 432/S 136 Ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A containing products.)

Client expense: $1,320,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Preservation of Antibiotics for Medical Treatment Act of 2011; Trans Fat Truth in Labeling Act of 2011; Poison-Free Poultry Act of 2011; Downed Animal and Food Safety Protection Act; White House Conference on Food and Nutrition Act; Food Safety Accountability Act of 2011; Foodborne Illness Reduction Act of 2011 [H.R.432] [H.R.965] [H.R.1486] [H.R.1382] [H.R.1487] [H.R.3704] [S.136] [S.216] [S.1157] [S.1211] [S.1529]

Client expense: $95,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, White House Office

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. H.R. 3067: Accelerating the End of Breast Cancer Act of 2011. The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $30,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

S 136 to establish requirements with respect to bisphenol A HR 432 to ban the use of bisphenol A in food containers and for other purposes

Client expense: $205,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 432-Poisonous Additives Act of 2011 4 Agency Advertising Guidelines H.R. 1-2011 Continuing Appropriations Front of Pack Labeling School Nutrition Standards

Client expense: $100,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Develop a strategy with respect to legislation aimed at banning or limiting the use of Bisphenol A. H.R. 432/S. 136. Ban Poisonous Additives Act of 2011.

Client expense: Not reported · Firm income: $30,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Develop a strategy with respect to legislation aimed at banning or limiting the use of Bisphenol A to ban the use of bisphenol A in food containers, and for other purposes: H.R. 432/S. 136. Ban Poisonous Additives Act of 2011.

Client expense: Not reported · Firm income: $30,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

HR 436/HR 488/HR 734/S 17/S 262 Medical Device Tax Repeal; (Provisions related to entire bill.) HR 4/HR 60/HR 144/HR 584/HR 705/S 18/S 72 The Small Business Paperwork Mandate Elimination Act of 2011; (Provisions related to the 1099 repeal.) S 365 Balanced budge Control Act of 2011; (Sections pertaining to healthcare expenditures, Medicare Part D drug benefits.) Combat Meth Epidemic Act of 2005; (Sections pertaining to electronic reporting and stop sale.) HR 2245 The Preserving Access to Life Saving Medications Act of 2011; (Drug shortage issues, those issues related to FDA, PDUFA IV and Energy & Commerce hearings on 9/23/11) Labor, HHS, and Education Appropriations Bill draft; (sections relating to efforts to defund PPACA.) HR141/HR 145/HR 215/HR 429, HR 636/S 16/S 193 To repeal the Patient Protection and Affordable Care Act and the Health Care and Education Reconciliation Act of 2010; (Provisions related to Health Care Reform repeal.) HR 965/S 1211 The Federal food, Drug, and Cosmetic Act to preserve the effectiveness of medically important antibiotics used in the treatment of human and animal diseases.) HR 432/S 136 ban Poisonous Additives Act of 2011: A bill to ban the use of Bisphenol-A in food containers, and for other purposes; (All provisions pertaining to the ban of food contact applications and the science used to support the ban on Bisphenol-A.)

Client expense: $1,380,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Legislation in the 112th H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th S. 847, the Safe Chemicals Act of 2011 The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. H.R. 2359, the Safe Cosmetics Act of 2011 The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011 The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer. H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011. The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely. House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals: The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products. The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products. Regulation and Legislative Intent: FDA Advocacy In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment. P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation. P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008 This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.

Client expense: Not reported · Firm income: $30,000

Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE

S. 513, Saving Kids From Dangerous Drugs Act of 2011 S. 136, Ban Poisonous Additives Act of 2011 H.R. 432, Ban Poisonous Additives Act of 2011 S. 174, Healthy Lifestyles and Prevention America Act S. 216, Food Safety Accountability Act of 2011 Issues related to FTC guidelines for advertising to children Issues related to the Supplemental Nutrition Assistance Program (SNAP) S. 1599 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act of 2012 Provisions relating to stimulus funding

Client expense: Not reported · Firm income: $90,000

Government targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE

H.R. 432-Poisonous Additives Act of 2011 4 Agency Advertising Guidelines H.R. 1-2011 Continuing Appropriations Front of Pack Labeling School Nutrition Standards

Client expense: $100,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Preservation of Antibiotics for Medical Treatment Act of 2011; Trans Fat Truth in Labeling Act of 2011; Poison-Free Poultry Act of 2011; White House Conference on Food and Nutrition Act; Food Safety Accountability Act of 2011; Foodborne Illness Reduction Act of 2011 [H.R.432] [H.R.965] [H.R.1486] [H.R.1382] [H.R.1487] [S.136] [S.216] [S.1157] [S.1211] [S.1529]

Client expense: $98,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Environmental Protection Agency (EPA), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, White House Office

S 136 to establish requirements with respect to bisphenol A HR 432 to ban the use of bisphenol A in food containers, and for other purposes

Client expense: $275,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE